Zdrowie i gospodarka · 16/10/2017
FDA Announces Draft Guidance for Industry on Post-Complete Response Letter Meetings
The FDA is releasing a draft guidance to clarify the criteria for post-complete response letter meeting requests and ensure well-managed meetings under the Generic Drug User Fee Act (GDUFA).
Source: Federal Register — Food and Drug AdministrationOpen original release →